Immune cells that prevent development of asthma identified

Asthma affects 6 % of the population and kills twenty thousand people in Europe each year. Patients suffering from the disease first develop, often at a very early age, a useless and even harmful immune reaction to airborne allergens (mite excrement, pet scales, pollens, etc.). Whenever exposed to these allergens, the patient's innate respiratory immune system is reactivated, thereby inducing a narrowing of the airways, which in turn results in insufficient oxygenation.

As the airborne antigens we take in with each breath are foreign to our bodies, this should elicit a response of the immune system. Moreover, ambient air contains a significant number of immunostimulatory molecules (bacterial endotoxins) that act as danger signals and should prompt the immune system to respond to the inhaled antigens. If this were so, the entire population would be asthmatic.

At GIGA Research Center (University of Liege), Fabrice Bureau and his team thus set out to understand the mechanisms which prevent the majority of the population from developing asthma and have discovered that certain cells present in the lungs are capable of inhibiting asthmatic reactions. These cells are regulatory macrophages which had not been characterized previously. The researchers have shown that these macrophages detect airborne antigens as well as concomitant immunostimulatory molecules.  Furthermore, they have demonstrated that when endotoxins are present in small amounts (as is the case in ambient air), regulatory macrophages paralyse the cells of the innate respiratory immune system, thus inhibiting the development of asthma in most people.  The researchers thus hypothesise that asthma can only develop when these regulatory macrophages are deficient.